Magnesium Sulfate Injection Rx
Generic Name and Formulations:
Magnesium sulfate 500mg/mL; soln for IM inj; or IV use after dilution; contains aluminum.
Various generic manufacturers
Indications for Magnesium Sulfate Injection:
Mild deficiency: 1g IM every 6 hours for four doses. Severe deficiency: 250mg/kg IM within a period of 4 hours if necessary; alternatively 5g may be added to one liter of 5% dextrose inj or 0.9% sodium chloride inj for slow IV infusion over a 3-hour period. TPN: usual range: 1–3g (8–24mEq) daily. Severe renal impairment: max 20g in 48 hours.
TPN for infants: usual range: 0.25–1.25g (2–10mEq) daily.
Heart block. Myocardial damage.
Renal impairment. Monitor serum magnesium levels; if repeated doses are given, test knee jerk reflexes before each dose. Have injectable calcium salt readily available to counteract magnesium intoxication. Elderly. Premature neonates. Pregnancy (Cat.D). Nursing mothers.
Additive CNS depressant effects with barbiturates, narcotics, other hypnotics; adjust dose. Potentiates neuromuscular blocking agents. Concomitant cardiac glycosides; use extreme caution, heart block may occur.
Magnesium intoxication (eg, flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression proceeding to respiratory paralysis.
Formerly known under the brand name Sulfamag.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|